data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Angion Biomedica
(NASDAQ:ANGN)
$1.12
-0.02[-1.75%]
At close: Jul 1
$1.14
0.0200[1.79%]
After Hours: 4:12AM EDT
Day High/Low1.06 - 1.13
52 Week High/Low1.03 - 14.18
Open / Close1.06 / 1.12
Float / Outstanding25.5M / 30M
Vol / Avg.387.5K / 169.2K
Mkt Cap33.6M
P/E-
50d Avg. Price1.49
Div / Yield-
Payout Ratio-
EPS0.58
Total Float25.5M

Angion Biomedica (NASDAQ:ANGN), Quotes and News Summary

Angion Biomedica (NASDAQ: ANGN)

Day High/Low1.06 - 1.13
52 Week High/Low1.03 - 14.18
Open / Close1.06 / 1.12
Float / Outstanding25.5M / 30M
Vol / Avg.387.5K / 169.2K
Mkt Cap33.6M
P/E-
50d Avg. Price1.49
Div / Yield-
Payout Ratio-
EPS0.58
Total Float25.5M
Benzinga - 2 days ago
Benzinga - 3 days ago
Benzinga - 3 days ago
Benzinga - 3 days ago
Benzinga - 3 days ago
Benzinga - 4 days ago
Benzinga - 4 days ago
Benzinga - 4 days ago
Benzinga - 4 days ago
Benzinga - May 23, 2022, 6:36AM
Benzinga - May 16, 2022, 4:39PM
Benzinga - Apr 18, 2022, 2:06PM
Benzinga - Apr 18, 2022, 6:16AM
Benzinga - Mar 30, 2022, 4:13PM
load more
Angion Biomedica Corp is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading with ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-11
REV
Q1 2022Est.ActualSurprise
EPS-0.430-0.480 -0.0500
REV920.000K1.648M728.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Angion Biomedica Questions & Answers

Q
How do I buy Angion Biomedica (ANGN) stock?
A

You can purchase shares of Angion Biomedica (NASDAQ: ANGN) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Angion Biomedica's (ANGN) competitors?
A

There are no as such competitors for Angion Biomedica.

Q
What is the target price for Angion Biomedica (ANGN) stock?
A

The latest price target for Angion Biomedica (NASDAQ: ANGN) was reported by Oppenheimer on Thursday, June 30, 2022. The analyst firm set a price target for 0.00 expecting ANGN to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Angion Biomedica (ANGN)?
A

The stock price for Angion Biomedica (NASDAQ: ANGN) is $1.12 last updated July 1, 2022, 8:00 PM UTC.

Q
Does Angion Biomedica (ANGN) pay a dividend?
A

There are no upcoming dividends for Angion Biomedica.

Q
When is Angion Biomedica (NASDAQ:ANGN) reporting earnings?
A

Angion Biomedica’s Q2 earnings are confirmed for Thursday, August 11, 2022.

Q
Is Angion Biomedica (ANGN) going to split?
A

There is no upcoming split for Angion Biomedica.

Q
What sector and industry does Angion Biomedica (ANGN) operate in?
A

Angion Biomedica is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.